private:stabilitech
|
1828957
|
Jun 1st, 2019 12:00AM
|
Stabilitech Biopharma Ltd
|
104
|
11.00
|
Open
|
Biotechnology
|
Jun 1st, 2019 02:30AM
|
Jun 1st, 2019 02:30AM
|
Stabilitech Biopharma Ltd has developed a novel proprietary technology platform which protects vaccines and other biological products against production losses, including lyophilisation losses, and provides thermal stability over a range of temperatures including temperature fluctuations. It has been applied successfully to a variety of vaccine and protein classes, including adjuvanted vaccines.
Stabilitech has now developed an oral delivery platform for vectors to enable the next generation of therapeutics to be generated in the gastrointestinal system.
|
Open
|
vaccine stability, oral gene therapy platform, biologic stability, influenza vaccine, Zika vaccine, cold chain enhancement, oral viral vectored proteins, thermostability
|
Open
|
|
|
|
GB
|
|
|
Stabilitech
|
|
Pharmaceuticals & Biotechnology
|
private:stabilitech
|
1828957
|
Mar 26th, 2018 12:00AM
|
Stabilitech Biopharma Ltd
|
80
|
11.00
|
Open
|
Biotechnology
|
Mar 26th, 2018 05:36PM
|
Mar 26th, 2018 05:36PM
|
|
Open
|
|
|
|
|
|
|
|
|
Stabilitech
|
|
Pharmaceuticals & Biotechnology
|
private:stabilitech
|
1828957
|
Feb 17th, 2018 12:00AM
|
Stabilitech Biopharma Ltd
|
73
|
11.00
|
Open
|
Biotechnology
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
Stabilitech Biopharma Ltd has developed a novel proprietary technology platform which protects vaccines and other biological products against production losses, including lyophilisation losses, and provides thermal stability over a range of temperatures including temperature fluctuations. It has been applied successfully to a variety of vaccine and protein classes, including adjuvanted vaccines.
Stabilitech has now developed an oral delivery platform for vectors to enable the next generation of therapeutics to be generated in the gastrointestinal system.
|
|
|
|
|
|
|
|
|
|
Stabilitech
|
|
Pharmaceuticals & Biotechnology
|
private:stabilitech
|
1828957
|
Feb 16th, 2018 12:00AM
|
Stabilitech Biopharma Ltd
|
73
|
11.00
|
Open
|
Biotechnology
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
Stabilitech Biopharma Ltd has developed a novel proprietary technology platform which protects vaccines and other biological products against production losses, including lyophilisation losses, and provides thermal stability over a range of temperatures including temperature fluctuations. It has been applied successfully to a variety of vaccine and protein classes, including adjuvanted vaccines.
Stabilitech has now developed an oral delivery platform for vectors to enable the next generation of therapeutics to be generated in the gastrointestinal system.
|
|
|
|
|
|
|
|
|
|
Stabilitech
|
|
Pharmaceuticals & Biotechnology
|
private:stabilitech
|
1828957
|
Feb 15th, 2018 12:00AM
|
Stabilitech Biopharma Ltd
|
73
|
11.00
|
Open
|
Biotechnology
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
Stabilitech Biopharma Ltd has developed a novel proprietary technology platform which protects vaccines and other biological products against production losses, including lyophilisation losses, and provides thermal stability over a range of temperatures including temperature fluctuations. It has been applied successfully to a variety of vaccine and protein classes, including adjuvanted vaccines.
Stabilitech has now developed an oral delivery platform for vectors to enable the next generation of therapeutics to be generated in the gastrointestinal system.
|
|
|
|
|
|
|
|
|
|
Stabilitech
|
|
Pharmaceuticals & Biotechnology
|
private:stabilitech
|
1828957
|
Feb 14th, 2018 12:00AM
|
Stabilitech Biopharma Ltd
|
73
|
11.00
|
Open
|
Biotechnology
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
Stabilitech Biopharma Ltd has developed a novel proprietary technology platform which protects vaccines and other biological products against production losses, including lyophilisation losses, and provides thermal stability over a range of temperatures including temperature fluctuations. It has been applied successfully to a variety of vaccine and protein classes, including adjuvanted vaccines.
Stabilitech has now developed an oral delivery platform for vectors to enable the next generation of therapeutics to be generated in the gastrointestinal system.
|
|
|
|
|
|
|
|
|
|
Stabilitech
|
|
Pharmaceuticals & Biotechnology
|
private:stabilitech
|
1828957
|
Feb 13th, 2018 12:00AM
|
Stabilitech Biopharma Ltd
|
73
|
11.00
|
Open
|
Biotechnology
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
Stabilitech Biopharma Ltd has developed a novel proprietary technology platform which protects vaccines and other biological products against production losses, including lyophilisation losses, and provides thermal stability over a range of temperatures including temperature fluctuations. It has been applied successfully to a variety of vaccine and protein classes, including adjuvanted vaccines.
Stabilitech has now developed an oral delivery platform for vectors to enable the next generation of therapeutics to be generated in the gastrointestinal system.
|
|
|
|
|
|
|
|
|
|
Stabilitech
|
|
Pharmaceuticals & Biotechnology
|
private:stabilitech
|
1828957
|
Feb 12th, 2018 12:00AM
|
Stabilitech Biopharma Ltd
|
73
|
11.00
|
Open
|
Biotechnology
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
Stabilitech Biopharma Ltd has developed a novel proprietary technology platform which protects vaccines and other biological products against production losses, including lyophilisation losses, and provides thermal stability over a range of temperatures including temperature fluctuations. It has been applied successfully to a variety of vaccine and protein classes, including adjuvanted vaccines.
Stabilitech has now developed an oral delivery platform for vectors to enable the next generation of therapeutics to be generated in the gastrointestinal system.
|
|
|
|
|
|
|
|
|
|
Stabilitech
|
|
Pharmaceuticals & Biotechnology
|
private:stabilitech
|
1828957
|
Feb 11th, 2018 12:00AM
|
Stabilitech Biopharma Ltd
|
73
|
11.00
|
Open
|
Biotechnology
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
Stabilitech Biopharma Ltd has developed a novel proprietary technology platform which protects vaccines and other biological products against production losses, including lyophilisation losses, and provides thermal stability over a range of temperatures including temperature fluctuations. It has been applied successfully to a variety of vaccine and protein classes, including adjuvanted vaccines.
Stabilitech has now developed an oral delivery platform for vectors to enable the next generation of therapeutics to be generated in the gastrointestinal system.
|
|
|
|
|
|
|
|
|
|
Stabilitech
|
|
Pharmaceuticals & Biotechnology
|
private:stabilitech
|
1828957
|
Feb 10th, 2018 12:00AM
|
Stabilitech Biopharma Ltd
|
73
|
11.00
|
Open
|
Biotechnology
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
Stabilitech Biopharma Ltd has developed a novel proprietary technology platform which protects vaccines and other biological products against production losses, including lyophilisation losses, and provides thermal stability over a range of temperatures including temperature fluctuations. It has been applied successfully to a variety of vaccine and protein classes, including adjuvanted vaccines.
Stabilitech has now developed an oral delivery platform for vectors to enable the next generation of therapeutics to be generated in the gastrointestinal system.
|
|
|
|
|
|
|
|
|
|
Stabilitech
|
|
Pharmaceuticals & Biotechnology
|